Indraprastha Medical Corporation Limited has filed its quarterly dematerialisation compliance certificate with stock exchanges, maintaining its regulatory obligations under SEBI guidelines. The healthcare services company submitted the mandatory documentation for the quarter ended 31st March 2026.

Regulatory Compliance Filing

The company submitted its confirmation certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 to both BSE and NSE on 7th April 2026. The certificate was issued by MUFG Intime India Private Limited, formerly Link Intime India Private Limited, which serves as the company's registrar and share transfer agent.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that securities received from depository participants for dematerialisation during the quarter were properly processed according to regulatory requirements. The registrar verified that all security certificates received for dematerialisation were confirmed or rejected within prescribed timelines.

The certificate confirms that securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are already listed. Additionally, the registrar confirmed that security certificates received were mutilated and cancelled after due verification by depository participants.

Stock Exchange Details

The filing was submitted to both major Indian stock exchanges where the company's shares are traded. The company maintains its listing compliance across these platforms, ensuring transparency and regulatory adherence for its shareholders and market participants.

The submission was signed by Priya Ranjan, AVP – Corporate Affairs & Legal, who serves as the Company Secretary & Compliance Officer. This quarterly filing demonstrates the company's commitment to maintaining regulatory compliance and transparency in its securities operations.

Indraprastha medical corporation Limited has announced the completion of tenure of its Independent Director Mr. Vinayak Chatterjee, marking the end of his second five-year term on the Board of Directors. The healthcare company informed stock exchanges about this board change through a formal intimation dated April 1, 2026.

Director Tenure Completion Details

Mr. Vinayak Chatterjee, holding Director Identification Number (DIN) 00008933, completed his second term of five consecutive years as Independent Director on March 31, 2026. The completion of his tenure resulted in his cessation as Director of the Company and as Member/Chairperson of respective Board Committees at the end of March 31, 2026.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. The intimation was sent to both BSE Limited and National Stock Exchange of India Limited, providing comprehensive details as required under the relevant SEBI circulars.

The formal communication was signed by Priya Ranjan, AVP - Corporate Affairs & Legal, who serves as the Company Secretary & Compliance Officer. The disclosure included an annexure with detailed information about the cessation, including the reason for change and date of cessation.

About the Company

Indraprastha Medical Corporation Limited operates as Indraprastha Apollo Hospitals with its registered office located at Sarita Vihar, Delhi-Mathura Road, New Delhi. The company holds Corporate Identity Number L24232DL1988PLC030958 and is accredited by Joint Commission International, reflecting its commitment to healthcare quality standards.